News from Conclusio

First non-executive chair appointed: 

Mike Proctor Conclusio non-executive chairjpg

Conclusio, is pleased to announce the appointment of Mike Proctor as its first non-executive chairman. Mike retired from his substantive NHS role as chief executive of York Foundation Trust 11 months ago and joins Conclusio from his most recent role as Interim chief operating officer at North Cumbria Trust. He brings 45 years of experience gained within the NHS, half
of which were spent in senior executive roles that included chief nurse, chief operating officer, deputy chief executive and chief executive. 

The appointment comes at a significant stage in Conclusio’s development, as it grows its presence, and client-base, in the health, social care, pharmaceutical and community pharmacy sectors. 

Speaking about Mike’s appointment, Conclusio Managing Director and Founder, James Roach says

“Conclusio prides itself on being a multi-disciplinary group of subject matter experts. Our core team can field decades of experience in the fields of health transformation, service framework development, data and analysis, market access and growth, communications and relationship management and programme management. Mike is the ideal person to provide the support and direction Conclusio needs now as it widens its reach and influence. His background in Secondary Care and Integrated Care Partnerships will be invaluable”


Download PDF below for full story

Conclusio appoints non-executive chair.pdf
Pharmacy Offer to Working Age Adults.pdf

BMJ - Opinion.  We must promote health and resilience in all ages to make the NHS                                           sustainable

October 2020

As the NHS begins its journey to embed the aims and objectives of the Long Term Plan, it is important that the principles of population health are not lost, say James Roach and Jeremy Hooper 

https://blogs.bmj.com/bmj/2020/10/15/we-must-promote-health-and-resilience-in-all-ages-to-make-the-n...

Pharmafield - Partnering with impact across the supply chain, post COVID-19

October 2020 by James Roach and Johnny Skillicorn-Aston

In a recent online seminar, leading health transformation consultancy, Conclusio, considered how intelligent targeting could identify opportunities for private and public partnership, particularly in the pharma industry, in a post COVID-19 NHS. Drawing on the experience of the 2008 financial crash, and from a range of data, the seminar reflected on the first phase of the pandemic and the insight it provides on where and how to intelligently target new areas of business development, widen the supply chain and partner with the NHS to support recovery and restoration.

https://pharmafield.co.uk/covid-19/partnering-with-impact-across-the-supply-chain-post-covid-19/

Pharmafield - Current trends in compliance. The COVID-19 pandemic has taught us many lessons, but are we missing an age-old one that we all need to learn and act upon?

September 2020 by Johnny Skillicorn-Aston and Andrew Clarke

In every crisis there are people waiting to exploit the situation for their gain and your loss. Johnny Skillicorn-Aston from health transformation consultancy, Conclusio, and Andrew Clarke from International Compliance Association (ICA), look at new compliance trends for professionals working in pharma and health supply chains.https://pharmafield.co.uk/in_depth/current-trends-in-compliance/


Specialised Medicines -  The vital role of community pharmacy during COVID-19 and beyond -  Community pharmacy is essential to supporting the ‘new normal’

September 2020 | By Amit Patel and Johnny Skillicorn-Aston

https://www.specialisedmedicine.co.uk/articles/the-vital-role-of-community-pharmacy-during-covid-19-...


Pharmafield -  Addressing the long-term effects of COVID-19

Addressing the long-term impacts on sickness and disease as a consequence of the COVID-19 pandemic, both causal and additive, will be a continuing challenge for the healthcare sector as it moves through the recovery and restoration agenda. 

Full article here:

https://pharmafield.co.uk/featured/addressing-the-long-term-effects-of-covid-19/
By Johnny Skillicorn-Aston and Jeremy Hooper -August 3, 2020

Specialised Medicines - We need to identify unmet need and create the solutions -  To start building a new model of care for pharmacy, the needs of working-age adults could be used as the basis for inter-contractor dialogue, say James Roach and Johnny Skillicorn-Aston of Conclusio

The homecare model for cancer must recognise the vital role of community pharmacists, argue James Roach and Johnny Skillicorn-Aston - Specialised Medicine May 2020

In the short to medium term, a cancer diagnosis focuses the mind on the disease and all that accompanies it: the prognosis, treatments, and effects on one’s life. However, for many people receiving a cancer diagnosis, especially those who are older, it will add to one or more pre-existing morbidities. Although treatment in the first instance may need to be acute, it will be the effective long-term management of an additional chronic condition that makes the difference to patients.

Full article here - https://www.specialisedmedicine.co.uk/articles/community-pharmacy-is-key-to-new-models-of-cancer-care/


Conclusio’s Johnny Skillicorn-Aston and James Roach consider the true meaning of patient-centricity in clinical trials : Pharma Times

 Full article herehttp://www.pharmatimes.com/thought_leadership/creating_common_endeavours_1332717

What’s the point of difference?

Pharma and the NHS - barriers to partnership working are breaking, it’s time for pharma to build on its differences to be more than a supplier.

James Roach and Johnny Skillicorn-Aston - Pharmafield Magazine

https://pharmafield.co.uk/pf-magazine/


 Johnny Skillicorn-Aston and James Roach argue that partnership working between the NHS and the pharmaceutical industry must now engage patients

In specialised medicines, we have witnessed a step change in the care of patients living with highly active relapsing multiple sclerosis (MS).  Across specialised commissioning, there now appears to be a real appetite for medicines innovation and optimisation that will contribute to the transformation and savings that the NHS wants to achieve as part of the LTP.  As NHS England Chief Executive Officer (CEO) Simons Stevens said: ‘Preparations are underway to make sure the NHS can adopt the next generation of treatments.

https://www.specialisedmedicine.co.uk/articles/a-step-change-in-specialised-medicines/


The important role community pharmacists can play as a source of initial advice and ongoing help in the management of heartburn and indigestion is one that is recognised by NICE and appreciated by customersOpportunity knocks for OTC Omeprazole. The OTC launch of Pyrocalm Control Omeprazole 20mg Gastro-Resistant Tablets offers an opportunity for pharmacists to both promote self-care and reduce prescribing
https://www.pharmacymagazine.co.uk/gut-feeling  


James Roach, in his NHS role,  looks at the future for biosimilar medicines, surveys a future landscape where medicines management will be performed at ICS level, and suggests that pharma can be a crucial player in NHS transformation

https://wilmingtonhealthcare.com/what-next-for-biosimilars/


James Roach and Johnny Skillicorn-Aston, Conclusio
January 2020

Driving innovation in a modern NHS - What is pharma’s role and what does it mean for patients? Pharmafield

https://pharmafield.co.uk/in_depth/driving-innovation-in-a-modern-nhs/


James Roach and Johnny Skillicorn-Aston, Conclusio 

December 2019

Let’s seize the opportunity to change the dynamic. Pharmacy needs to push the case for a change in the point of patient interaction and so help manage access pressures. Pharmacy Magazine -

 https://www.pharmacymagazine.co.uk/lets-seize-the-opportunity-to-change-the-dynamic


Johnny Skillicorn-Aston, Director of Engagement and communication, Conclusio

October 2019

A recent roundtable event attended by academics, nutrition experts and health and industry leaders brought into sharp focus the issue of malnutrition and its consequences for health and wellbeing. 

https://flickread.com/edition/html/index.php?pdf=5ddbee05a2dd8#15 


From elsewhere - Amanda Barrell writing in PharmaPhorum

A move towards integrated care systems (ICS), complete with new primary care roles, and a greater focus on public health is shaking the healthcare system to its core. But what does this mean for industry?

Mike Proctor, recently retired chief executive of York Teaching Hospital NHS Foundation Trust, quoted in the articles "Iindustry could become a crucial part of this new world – but routes to success vary across the country." 
He advised delegates to adopt a flexible, regional approach, be prepared to move from national to local priorities, and to build relationships with the new decision makers.
“There is a dream of a truly integrated social care, primary care, secondary care and mental health care. We do believe this is the right thing to do but the bottom line is there is no one size to fit all,” he said, adding that the only unifying factor was reducing hospital admissions. Don’t sell boxes, sell solutions. Develop products that keep people out of hospital – that is key. If you can find ways to keep people out of hospital and you can support that in some way, the door is open,”


Events:

Ethical Medicines Industry Group - 11 November 2019

James Roach speaking to EMIG today and says ' 'The time couldn't be better for NHS and industry partnerships; but effective partnerships need co-ownership of the challenge and equity across risks and benefits.'

PHOTO-2019-11-11-12-13-41jpg


HSJ Awards 6 November - 

James Roach part of the judging panel and presenting award 

PHOTO-2019-11-07-10-33-592857jpg


Driving Forward Market Access in the new NHS Environment. Mtech Access.  25th September 2019.   http://www.mtechaccess.co.uk/seminar-new-nhs-environment/#engaging-with-impact 
James Roach presented on Engaging with Impact: Market Access and the new NHS.

Video at   https://www.youtube.com/watch?v=a51I5X2hOtw&t=24s.



HSJ Life Sciences Forum - June 2019

James Roach speaking as a part of the panel